24/7 Wall St. on MSN2h
Look Out, Interest Rate Cuts Could Be Over: Buy These High-Yield Passive Income Stars NowWhen the Federal Reserve met in December, it threw the stock market and Wall Street a pretty big curveball when it revealed ...
DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...
Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...
Opinion
1dOpinion
Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...
In this article, I employ AI to rank 19 repurposed drugs and supplements by effectiveness against metastatic cancer. To add ...
Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...
Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...
The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...
Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.
Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...
B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback